```html

Gastric Lymphoma – A Complete Patient‑Friendly Guide

Overview

Gastric lymphoma is a type of cancer that originates in the lymphoid tissue of the stomach. Unlike the more common adenocarcinoma of the stomach, gastric lymphoma arises from B‑cells (the most frequent) or, rarely, T‑cells that are part of the immune system. It accounts for ~1–4% of all gastric malignancies and ~10–15% of all extranodal (outside the lymph nodes) lymphomas worldwide.

Both men and women can develop gastric lymphoma, but the disease shows a slight male predominance (about 55% male). The median age at diagnosis is 55–60 years, though cases are reported from adolescence to the elderly.

Incidence varies geographically: higher rates are seen in East Asia (especially Japan and China) where Helicobacter pylori infection is common, and lower rates in North America and Western Europe.

Symptoms

Gastric lymphoma often grows slowly, so symptoms may be vague at first. The list below includes the most frequent presentations, each with a brief description.

General & Constitutional

• Unexplained weight loss – loss of >5% body weight over 6 months without dieting.
• Fatigue – due to anemia or systemic inflammation.
• Fever or night sweats – “B symptoms” common in many lymphomas.

Gastrointestinal

• Epigastric discomfort or pain – dull, burning, or cramping sensation in the upper abdomen.
• Early satiety – feeling full after a small amount of food.
• Nausea & vomiting – may be persistent or occur after meals.
• Gastrointestinal bleeding – manifests as hematemesis (vomiting blood), melena (black, tarry stools), or occult blood loss leading to anemia.
• Loss of appetite – often linked with early satiety.
• Abdominal mass – a palpable lump is rare but can be felt in advanced disease.

Complication‑related

• Perforation – sudden severe abdominal pain if the stomach wall ruptures.
• Obstruction – vomiting and inability to tolerate oral intake due to tumor blockage.

Causes and Risk Factors

Gastric lymphoma is not caused by a single factor; rather, a combination of infections, immune dysregulation, and genetic changes increases risk.

Infectious Agents

• Helicobacter pylori – long‑standing infection is linked to the most common subtype, mucosa‑associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori can lead to regression in up to 80% of early cases (Mayo Clinic).
• Epstein‑Barr virus (EBV) – associated with some high‑grade T‑cell and B‑cell gastric lymphomas, especially in immunosuppressed patients.

Immune‑Related Conditions

• Autoimmune gastritis
• Immunodeficiency (e.g., HIV/AIDS, congenital immunodeficiencies)
• Organ transplantation and long‑term immunosuppressive therapy

Genetic & Environmental Factors

• Family history of lymphoma or other hematologic malignancies.
• Exposure to certain pesticides and industrial chemicals (limited evidence).
• High‑salt diet and smoking may increase the risk of gastric adenocarcinoma and possibly lymphoma, but data are inconclusive.

Demographic Risk

• Age >50 years
• Male gender (slight increase)
• Geographic regions with high H. pylori prevalence.

Diagnosis

Because early symptoms overlap with benign conditions (e.g., peptic ulcer disease), a systematic approach is essential.

Initial Evaluation

1. Medical history & physical exam – focus on B symptoms, risk factors, and abdominal examination.
2. Laboratory tests – CBC (look for anemia), liver panel, LDH, β2‑microglobulin, and H. pylori testing (urea breath test, stool antigen, or serology).

Imaging Studies

• Upper endoscopy (EGD) – first‑line tool; allows direct visualization, biopsy, and assessment of ulceration or mass.
• Endoscopic ultrasound (EUS) – evaluates depth of tumor invasion and regional lymph nodes; useful for staging.
• CT scan of chest/abdomen/pelvis – assesses distant spread and helps in treatment planning.
• Positron emission tomography (PET‑CT) – detects metabolically active disease; increasingly used for staging and response assessment.

Pathology

Biopsy specimens are examined by a hematopathologist. Key diagnostic criteria include:

• Immunohistochemistry (CD20, CD79a for B‑cells; CD3 for T‑cells).
• Genetic studies – e.g., API2‑MALT1 translocation in MALT lymphoma.
• Classification according to WHO 2022 lymphoma categories (e.g., gastric MALT lymphoma, diffuse large B‑cell lymphoma).

Staging

The Lugano modification of the Ann Arbor system is most commonly used for gastrointestinal lymphomas. Stages I–IV describe the extent of disease from localized to disseminated.

Treatment Options

Therapy is individualized based on lymphoma subtype, stage, patient age, and comorbidities.

1. Eradication Therapy (First‑line for Early‑Stage MALT Lymphoma)

• Triple regimen: clarithromycin 500 mg BID + amoxicillin 1 g BID (or metronidazole 500 mg TID) + proton‑pump inhibitor (PPI) BID for 14 days.
• Success rates: 70–80% complete remission when H. pylori is present (Cleveland Clinic).
• Follow‑up endoscopy at 3–6 months to document response.

2. Radiotherapy

Low‑dose involved‑field radiation (30 Gy in 15 fractions) is highly curative for localized (stage I‑II) disease, especially when antibiotics fail.

3. Chemotherapy

• R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) – standard for aggressive B‑cell lymphomas such as diffuse large B‑cell lymphoma (DLBCL).
• Bendamustine + rituximab – an alternative for patients who cannot tolerate anthracyclines.
• For T‑cell subtypes, regimens like CHOP or newer agents (e.g., brentuximab vedotin) may be used.

4. Targeted & Immunotherapy

• Rituximab (anti‑CD20 monoclonal antibody) – often combined with chemotherapy or used alone in low‑grade disease.
• PD‑1 inhibitors** (e.g., nivolumab) – under investigation for relapsed/refractory gastric lymphoma.

5. Surgery

Rarely needed today. Indications include:

• Complications (perforation, uncontrolled bleeding, obstruction).
• Diagnostic uncertainty when endoscopic biopsies are non‑diagnostic.

6. Supportive & Lifestyle Care

• Nutrition support – high‑protein, easily digestible diet; consider dietitian referral.
• Management of anemia (iron, B12, or transfusion as needed).
• Prophylactic antibiotics or antivirals when on immunosuppressive chemotherapy.

Living with Gastric Lymphoma

Beyond medical treatment, daily habits and self‑care can improve quality of life and reduce treatment side effects.

Nutrition

• Eat small, frequent meals; avoid large, heavy dishes that increase gastric pressure.
• Limit spicy, acidic, or highly seasoned foods if they trigger discomfort.
• Focus on lean protein (fish, poultry, tofu), cooked vegetables, and whole grains.
• Stay hydrated—aim for 1.5–2 L of fluid daily unless fluid restriction is advised.

Physical Activity

Moderate activity (walking, gentle yoga, swimming) for 150 minutes per week helps maintain stamina and reduces fatigue.

Medication Adherence

Set reminders, use pill organizers, and keep a medication list to avoid missed doses—critical for chemotherapy and antibiotic regimens.

Monitoring

• Track weight, appetite, and bowel habits weekly.
• Report new or worsening abdominal pain, vomiting, or bleeding to your oncology team promptly.

Psychosocial Support

Consider counseling, support groups, or patient‑advocacy organizations (e.g., Lymphoma Research Foundation). Emotional well‑being is strongly linked to treatment tolerance.

Prevention

Because many risk factors are modifiable, the following steps can lower the chance of developing gastric lymphoma:

• Eradicate Helicobacter pylori if testing is positive—standard triple therapy is highly effective.
• Adopt a healthy diet rich in fruits, vegetables, and fiber; limit processed meats and excessive salt.
• Quit smoking and limit alcohol consumption (< 2 drinks/day for men, < 1 drink/day for women).
• Maintain a healthy weight (BMI 18.5–24.9) through balanced diet and regular exercise.
• For immunocompromised patients, follow infection‑prevention guidelines and keep vaccinations up to date (e.g., influenza, pneumococcal).

Complications

If left untreated or if disease progresses, several serious problems can arise:

• Gastrointestinal bleeding – may lead to severe anemia or hemodynamic instability.
• Perforation – rupture of the stomach wall causing peritonitis, a surgical emergency.
• Obstruction – food cannot pass, resulting in vomiting, dehydration, and malnutrition.
• Transformation to high‑grade lymphoma – especially in untreated MALT lymphoma.
• Secondary infections – due to chemotherapy‑induced immunosuppression.
• Treatment‑related toxicity – cardiac (anthracycline), renal (cisplatin), or neuropathy (vincristine).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe abdominal pain that does not improve with rest.
• Vomiting blood (bright red) or coffee‑ground material.
• Black, tarry stools (melena) or bright red rectal bleeding.
• Fever > 38.5 °C (101.3 °F) accompanied by chills.
• Rapid heartbeat, dizziness, or fainting (possible sign of major bleeding).
• Inability to keep any food or fluids down for more than 24 hours.

---

Sources: Mayo Clinic; Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH) – National Cancer Institute; World Health Organization (WHO); Cleveland Clinic; American Society of Clinical Oncology (ASCO) guidelines; peer‑reviewed articles, Journal of Clinical Oncology 2022, Blood 2021.

```